SCHEMBL3497288

SCHEMBL3497288

Cc1ccc(Nc2ncc(C#N)c(NC3CC(C)(C)N(C)C(C)(C)C3)n2)cc1-n1cnnn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 4/20 0.42
SYK P43405 2/20 0.40
SLC2A1 P11166 1/20 0.37
LRRK2 Q5S007 3/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
AURKA O14965 2/20 0.36
CSNK2A2 P19784 5/20 0.35
CSNK2A1 P68400 4/20 0.35
PKMYT1 Q99640 2/20 0.35
PRKCD Q05655 1/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34
PRKD3 O94806 1/20 0.34
MAP4K4 O95819 1/20 0.34
PAK4 O96013 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1740839 0.91 PRKCQ (0.47) PRKCQSYKLRRK2AURKACSNK2A2
SCHEMBL3494407 0.90 SYK (0.40) PRKCQSYKSLC2A1LRRK2KDM4E
SCHEMBL3496733 0.88 PRKCQ (0.55) PRKCQSYKLRRK2KDM4EMEN1
SCHEMBL3493908 0.86 CSNK2A2 (0.49) PRKCQSYKCSNK2A2CSNK2A1CDK7
SCHEMBL20752089 0.83 SYK (0.43) SYKSLC2A1LRRK2KDM4EMEN1
SCHEMBL3495601 0.83 PRKCQ (0.57) PRKCQSYKLRRK2KMT2ACSNK2A2
SCHEMBL1742240 0.82 PRKCQ (0.49) PRKCQSYKLRRK2KDM4EMEN1
SCHEMBL1740739 0.82 SYK (0.41) PRKCQSYKLRRK2AURKACSNK2A2
SCHEMBL3495493 0.81 PRKCQ (0.55) PRKCQSYKLRRK2KDM4EALDH1A1
SCHEMBL3496006 0.81 PRKCQ (0.57) PRKCQSYKLRRK2AURKAPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885SYK 460/4885SLC2A1 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.